FCCC LOGO Faculty Publications
Moten AS , Zhao H , Howell K , Nadler A , Reddy SS , von Mehren M , Movva S , Farma JM
Soft tissue sarcoma of the extremity: Characterizing symptom duration and outcomes
Surg Oncol. 2019 Jun;29 :190-195
Back to previous list
BACKGROUND: We sought to investigate how the interval between symptom onset and diagnosis of soft tissue sarcoma (STS) of the extremity was associated with survival. METHODS: Patients treated for extremity STS years 2006-2015 were stratified by symptom duration: at least two, six or twelve months between symptom onset and diagnosis. Chi-square tests compared patient and tumor-related characteristics based on symptom duration. Survival analysis included Cox regression and Kaplan-Meier estimates. RESULTS: Of 113 patients included, mean age was 56.7 years, 52.2% were male, and 75.2% were white. Median tumor size was 75mm, 48.7% were grade 3, and 38.1% were stage I. With symptom duration of either at least 6 or 12 months, a greater proportion of patients who experienced the specified symptom duration had lower grade tumors (p<0.01 and p=0.01, respectively) and lower stage disease (p<0.01 and p=0.02, respectively) than those who did not. Among all patients, survival estimates were similar between those who experienced a symptom duration of 2 (p=0.12), 6 (p=0.18) or 12 (p=0.61) months and those who did not. CONCLUSION: Patients with extremity STS who tolerated a longer symptom duration had less advanced disease. Reasons for prolonged symptom duration and methods to address these factors warrant further investigation.
1879-3320 Moten, Ambria S Zhao, Huaqing Howell, Krisha Nadler, Ashlie Reddy, Sanjay S von Mehren, Margaret Movva, Sujana Farma, Jeffrey M Journal Article Netherlands Surg Oncol. 2019 Jun;29:190-195. doi: 10.1016/j.suronc.2019.05.016. Epub 2019 May 21.